Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005988 · ClinicalTrials.gov registry record · Phase 1

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

A Phase 1 study of Lymphoma and Leukemia, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
2
Study locations

NCT00005988: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by Dana-Farber Cancer Institute.

NCT00005988 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005988, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the donor bone marrow with the patient's white blood cells and a monoclonal antibody may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of bone marrow transplantation with specially treated bone marrow in treating patients who have hematologic cancer that has not responded to previous therapy.

Conditions Studied

Lymphoma Leukemia Myelodysplastic Syndromes Graft-Versus-Host Disease Myeloma

Interventions

  • DRUG cyclophosphamide
  • DRUG methylprednisolone
  • DRUG leucovorin calcium
  • DRUG methotrexate
  • DRUG cyclosporine

Study Locations (2)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Minnesota

  • University of Minnesota Cancer Center - Minneapolis

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2000-02
Est. Completion 2002-03-08
Phase Phase 1
Dana-Farber Cancer Institute

781 total trials

What the finished NCT00005988 record still lists

NCT00005988 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00005988 reports a single indexed study location in Massachusetts, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00005988 about?

NCT00005988 is a clinical study titled "Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy". RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the donor bone marrow with the pa...

What is the current status of trial NCT00005988?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2000-02. Estimated completion is 2002-03-08.

What conditions does trial NCT00005988 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Graft-Versus-Host Disease, Myeloma.

What interventions are being tested in trial NCT00005988?

The interventions under investigation include: cyclophosphamide (DRUG), methylprednisolone (DRUG), leucovorin calcium (DRUG), methotrexate (DRUG), cyclosporine (DRUG).

Who is sponsoring clinical trial NCT00005988?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005988 being conducted?

This trial has 2 study locations across Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00005988's enrollment target sits among peer trials

5 289th of 299 higher than 9 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00005988, the US trial registry maintained by the National Library of Medicine. NCT00005988 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.